

## Press release

# Deeplex<sup>®</sup> Myc-TB: Pursue the global deployment of the innovative solution for predicting antibiotic resistance in tuberculosis

Lille (France), Shah Alam (Malaysia) — March 30<sup>th</sup>, 2021

**GenoScreen and ScienceVision announce an agreement to commercialize the Deeplex<sup>®</sup> Myc-TB test in Malaysia, Myanmar and Brunei.**

With 10 million new cases per year, and 1.4 million deaths in 2019, tuberculosis remains the world's deadliest bacterial infectious disease. The emergence and spread of multidrug-resistant mycobacterial strains (causing more than 400,000 new cases in 2019) are causing a global public health problem that complicates the fight against TB. Southeast Asia is one of the most affected regions in the world, accounting for more than 40% of global TB cases and deaths.

Deeplex<sup>®</sup> Myc-TB is an innovative test for predicting antibiotic resistance in *Mycobacterium tuberculosis* developed by GenoScreen. It allows, thanks to its innovative deep sequencing engineering, to simultaneously study the resistance to 15 antibiotic molecules<sup>1</sup>. This test is based on the amplification and targeted sequencing of more than 20 genetic regions of the pathogen. It allows a complete diagnosis of the antibiotic resistance profile and the genotype of the bacteria, from a clinical sample, without a prior culture step.

Through this agreement, Genoscreen confirms its commitment to the fight against this pandemic.

*« This distribution agreement will allow TB patients in Malaysia, Myanmar and Brunei to benefit from the most appropriate care in terms of speed and efficiency ».*

*Adel HOUHOU, Marketing & Business Affairs Manager, GenoScreen*

National TB Programme (NTP) in Malaysia, Myanmar and Brunei has been implemented with same vision to be a tuberculosis free nation. Essentially the key strategies of NTP are 1) to ensure universal access to timely and quality diagnosis and treatment of all forms of TB 2) to prevent development of drug resistance TB in the country 3) to promote the early detection and treatment of TB. There are three major challenges in achieving these strategies which are long culture time that slows down the TB treatment given to patients, unreliable drug susceptibility testing (DST) phenotypic testing result and low detection of drug resistance profile.

ScienceVision as the genomics catalyst aims to increase the adoption of Deeplex<sup>®</sup> Myc-TB by distributing this solution to clinical research facilities and healthcare service providers in Malaysia, Myanmar, and Brunei. Deeplex<sup>®</sup> Myc-TB is a fast all-in-one solution, deep sequencing-based assay for identification, genotyping and antibiotic resistance prediction of *Mycobacterium tuberculosis*. The utilities of Deeplex<sup>®</sup> Myc-TB will overcome the major three challenges faced by the clinical research

<sup>1</sup> 1<sup>st</sup> line anti-tuberculosis drugs (rifampicin, isoniazid, pyrazinamide and ethambutol), 2<sup>nd</sup> line anti-tuberculosis drugs (levofloxacin, moxifloxacin and ciprofloxacin, kanamycin, amikacin, capreomycin and streptomycin), as well as new antibiotic molecules (bedaquiline, linezolid)



facilities and healthcare service provider in Malaysia, Myanmar, and Brunei, facilitating the implementation and effectiveness of key strategies under National TB Programme (NTP).

*« The partnership with Genoscreen to distribute Deeplex® Myc-TB in Malaysia, Myanmar and Brunei will transform our way of detection and treatment for TB, and we are one step closer to be TB-free nation ».*

*Ben Foong, General Manager, ScienceVision*

## Press contact

---

Aurélien FALCOT, Communication Officer, GenoScreen :  
aurelien.falcot@genoscreen.com — +33(0) 359 317 402

Teow Kok Sin, Application Scientist, ScienceVision :  
koksins@sciencevision.com.my — +6019-3341 615

## About GenoScreen

---

**GenoScreen** is a French biotech company founded in 2001, specialized in genomics and bioinformatics.

**Its strategy of innovation** through research enables it to offer services and innovative solutions to academic and industrial research teams to analyze and exploit the DNA characteristics of any type of genome and metagenome.

**Its portfolio of activities** comprises 3 poles:

- **A Services division** that provides standardized and custom analyses services, under ISO certification, on all genome types (human, animal, plant, microbial).
- **An Expertise division**, that provides consultancy services for companies seeking to implement genomics projects. Genoscreen is specifically recognized for its expertise in microbial genome and metagenome analysis.
- **An Innovation division** charged with the production and commercialization of analytical solutions to meet the demand of various industries (health, cosmetics, agriculture, agronomy, environmental).

**Its mission:** to unlock the potential of genomic information for the benefit of human health and the environment.

## About ScienceVision

---

**ScienceVision** is a Malaysia biotech company founded in 2007, specialized in genomics and bioinformatics.

**We take pride** in becoming the catalyst in increasing the technology adoption by becoming the active link between our customers and technology.

**Its portfolio of activities** comprises 3 poles:

- **Our Vision** as a team of highly motivated individuals with the aim of increasing the utilization and adoption of the latest genomics solutions through the creation of an ecosystem that comprises molecular biology tools, next generation sequencing and genome informatics
- **Our Passion** as strong believer in market development through scientific collaboration and our passion in science is demonstrated in various international scientific publications bearing our



name and this is only possible through the exciting setup of our unique teams of talented bioinformaticians and genome scientists.

- **Our People** as talent development is key to our growth. With our continuous leadership program, we have successfully created a high competency commercial and service & support team and our scientific drive is parallel with our growing passion which has resulted in the successful development of key applications with regional utilization.

**Its mission:** To unlock the power of genome to improve human health

